Loading
Latest filing published 19 May 2022 for Gain Therapeutics, Inc., €7,657.
No signal scores available.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Salvatore Calabrese, listed as finance chief, appears in our data through filings on Gain Therapeutics, Inc. shares, published by SEC (Form 4). We count 2 filings, every one of them for a trade on 19 May 2022.
On the market, this insider has only ever bought: 2 purchases, €15k in total. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant.
The newest entry dates from 23 May 2022: an open-market purchase of €7,657, in Gain Therapeutics, Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
1 of 1 declaration